Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2809206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Shuchang Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, 475004 Kaifeng, Henan, China. Hauptthemen laut MEDLINE: Glioblastoma, Receptors, Chimeric Antigen, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Adoptive chimeric antigen receptor (CAR) T cells designed to recognize specific tumor antigens have shown promising results in cancer therapy. While CAR T cell therapy has demonstrated notable clinical effectiveness for hematologic disease, efforts to develop therapies for solid tumors, including glioblastoma (GBM), have been hampered by heterogeneity, an immunosuppressive tumor microenvironment, and difficulty in trafficking. Several specific tumor antigens, such as IL13Rα2, EGFRvIII, and HER2, have been attempted in clinical trials; however, limited efficacy has been observed. In this review, we discuss the current status of CAR T therapy for GBM in clinical trials and highlight the potential target antigens for CAR T cells. Additionally, we summarize the mechanisms used to enhance their efficacy and explore the challenges and future prospects of CAR T cell therapy for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, 475004 Kaifeng, Henan, China.
- Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, 475004 Kaifeng, Henan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, S., Sun, H., Choi, S. I., & Yin, J. (2023). Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2809206
Vancouver
Zhou S, Sun H, Choi SI, Yin J. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2809206
BibTeX
@article{Zhou2023,
author = {Zhou, Shuchang and Sun, Han and Choi, Sun Il and Yin, Jinlong},
title = {Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2809206}
}
EUVIMED